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Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that
time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now
classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to
be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many
large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as
a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of
a 3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance
of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature
describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider
previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16.
Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to
be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants
the need for in-depth research on the biochemistry and biology of this mucin. A renewed focus on MUC16 is likely
to culminate in novel and more efficient strategies for the detection and treatment of ovarian cancer.
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CA125 is best known as a biomarker to monitor epithe-
lial ovarian cancer and for the differential diagnosis of
pelvic masses [1,2]. Serum levels of CA125 are routinely
monitored in patients with ovarian cancer, and an in-
crease from an individualized nadir concentration is a
prognostic indicator of cancer recurrence. An extensive
body of work has been published on the interpretation
of CA125 assay results, with particular focus given to
CA125 in ovarian cancer patients undergoing therapy
[1-12]. Understanding of the clinical applicability of the
CA125 assay has come from basic, translational, and
clinical studies conducted since the early 1980’s [13-20].
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unless otherwise stated.assay to measure CA125 in clinical samples is limited by
an incomplete understanding of the biochemical struc-
ture of this antigen. Here, we will review the current
knowledge of the structure of CA125 and provide crit-
ical appraisal of factors that may interfere with accurate
and sensitive measurement of this biomarker.
CA125 is a repeating peptide epitope of the mucin
MUC16 [21,22], which promotes cancer cell proliferation
and inhibits anti-cancer immune responses [23-26]. Our
discussion of the biological role of MUC16 will focus on its
importance in cancer cell signaling, metastasis, regulation
of immune responses and on anti-cancer therapeutic strat-
egies that target this mucin. A major goal of this review is
to highlight gaps in our knowledge of the biochemistry
and biology of MUC16/CA125 to provide a framework of
unanswered questions to be addressed in future studies.CA125 as a clinical biomarker
CA125 has been extensively investigated as a biomarker in
three separate clinical scenarios: (1) as a screening test fortd. This is an Open Access article distributed under the terms of the Creative
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between benign and malignant disease in pre- and post-
menopausal women presenting with pelvic masses, and
(3) to monitor response to therapy in women with ovar-
ian cancer.
CA125 as a screening modality for ovarian cancer
An increase (beyond a cut-off of 30–35 U/ml) is generally
observed in blood samples that are serially obtained from
women with ovarian cancer [27]. Therefore, for screening,
longitudinal monitoring of serum CA125 levels is likely to
be more useful than a single measurement. The Risk of
Ovarian Cancer Algorithm (ROCA) predicts the probabil-
ity of ovarian cancer based on such longitudinal monitor-
ing of CA125 [27,28]. ROCA allows triaging of patients
into groups with low, intermediate and high risk of ovar-
ian cancer.
ROCA was developed after retrospective analysis of
serum samples obtained from an ovarian cancer screen-
ing trial of 5550 women conducted in Sweden [29,30].
This trial concluded that serum CA125 monitoring will
be most beneficial in post-menopausal women. In this
cohort, the serum CA125 test provides sensitivity and
specificity of 91 and 94.5%, respectively.
The largest fully reported ovarian cancer screening trial
that used CA125 as a biomarker (in combination with
ultrasonography) was conducted in the United Kingdom
with a cohort of 22,000 women [31]. A total of 41 women
tested positive for ovarian cancer based on CA125 and
ultrasound. Only eleven of these 41 cases were found to
be truly positive for ovarian cancer after subsequent surgi-
cal investigation. Eight women who had screened negative
for ovarian cancer developed the disease 12–22 months
after the initial screen.
Enthusiasm for the success of combination of CA125
assay and transvaginal ultrasound screening is tempered
by the negative results from the Prostate, Lung, Colorectal,
and Ovarian Cancer (PLCO) trial [32-34]. In this ran-
domized control trial of 78,216 subjects, women in the
intervention arm were screened for CA125 levels and
transvaginal ultrasound. There was no improvement in
mortality (the primary endpoint of this study) in this trial.
The PLCO trial did not employ ROCA. A retrospective
analysis [35] has suggested that the use of ROCA in PLCO
would not have led to statistically significant mortality
benefit of screening, in part because of the long delay (one
year) between screens and the absence of a standardized
diagnostic algorithm [32].
Given the low prevalence of ovarian cancer in the gen-
eral population, it is estimated that a good clinical trial to
develop a screening paradigm for ovarian cancer would re-
quire recruitment of >150,000 women [30,36]. The United
Kingdom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) accrued a total of 202,638 post-menopausalwomen between 2001 and 2005 [37]. Subjects were ran-
domized into (1) control, (2) serum CA125 plus trans-
vaginal ultrasound, and (3) transvaginal ultrasound only
groups [38]. The ROCA was used to triage women in the
second group to low, intermediate and high-risk cate-
gories. Subjects in the intermediate-risk category were
monitored for CA125 levels every 4 months, and if they
continued to show increased risk for ovarian cancer, were
monitored by ultrasound scans. The subjects in the high-
risk category underwent transvaginal ultrasound scans
[38]. Final results from this trial are expected in 2015. In-
terim analysis from this trial has led to the promising find-
ing that 47.1% of women testing positive after combined
assessment with CA125 test and transvaginal ultrasound
had stage I or II disease [38]. The combined use of ROCA
and ultrasound, strict guidelines for follow up in 3–4
months after elevated CA125 is detected and a well-
coordinated plan for screening patients across all partici-
pating sites are advantages of the UKCTOCS over the
PLCO study design that are expected to contribute to suc-
cessful identification of a screening strategy for ovarian
cancer [35,39]. Survival data from the UKCTOCS trial is
expected in 2015.
CA125 as a diagnostic marker for ovarian cancer
The majority of patients with ovarian cancer are periodic-
ally assayed for CA125. An increase in concentration of
CA125 above a nadir is an indicator of disease recurrence
[40-42]. Another important potential application of the
CA125 assay is in distinguishing benign pelvic masses
from ovarian cancer [43]. The Risk of Malignancy Index
(RMI) combines serum CA125 concentrations with ultra-
sound and menopausal status to distinguish between be-
nign disease and cancer [44]. Recent studies suggest that a
Risk of Ovarian Malignancy Algorithm (ROMA) incorpor-
ating CA125 and HE4 levels in serum is likely to produce
a test of high sensitivity and specificity in identifying ovar-
ian cancer patients [45-47].
Currently, HE4 is the only biomarker, other than CA125,
that has been approved by the U.S. Food and Drug Admin-
istration as a diagnostic marker for ovarian cancer [48,49].
Another algorithm, OVA1, uses CA125, apolipoprotein
A1, transthyretin, transferrin and β2-microglobulin and
takes into account data from ultrasound imaging and
menopausal status of patients [50].
Mesothelin, osteopontin, CA15.3, CA19.9, AFP, KLK6
and several others have been investigated and suggested
as potential biomarkers for ovarian malignancy. A recent
multi-center effort to test the sensitivity and specificity of
panels of markers conducted using the serum samples ob-
tained from PLCO has been reported [51]. None of the
panels of markers tested in this trial improve on the sensi-
tivity and specificity of CA125 in screening or ovarian can-
cer diagnosis [52,53]. The conclusion from the important
Figure 1 MUC16 structure. Model shows the three domains of
MUC16 and potential location of the CA125 epitope in a
tandem repeat.
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continues to be, and for the foreseeable future will persist
as, the predominant and most clinically useful biomarker
for ovarian cancer. It is therefore imperative that signifi-
cant effort be put forth to clearly understand the chemical
nature of this antigen with the express intent of improving
the widely used CA125 assay.
Biochemistry of CA125
CA125 was first identified in a screen of monoclonal anti-
bodies raised against the ovarian cancer cell line OVCA433
[13,54]. One antibody, OC125, recognized an antigen in
ovarian cancer specimens which was designated as CA125
[13-17,55]. Several antibodies, M11, VK8 and OV197
among them, were subsequently developed against CA125
[56,57]. Based on their binding specificities, CA125-
specific antibodies are grouped as belonging to the OC125,
M11 or OV197 families [58-61].
Initial gel filtration experiments suggested that CA125
had a molecular weight as high as 2 million Da [62].
Hanisch and colleagues demonstrated that CA125 activ-
ity was contained in a high molecular weight mucinous
fraction isolated from human milk [63]. Isopycnic dens-
ity gradient centrifugation led to isolation of CA125 ac-
tivity in a fraction with the buoyant density of 1.41 g/ml,
a density that is typically observed for most human mu-
cinous glycoproteins [63].
A more definitive study on the molecular characterization
of CA125 by Davis et al. showed that CA125 isolated
from OVCA433 cells had a buoyant density of 1.42 g/ml
whereas the antigen in human serum and milk had a
density of 1.46 g/ml and 1.39 g/ml, respectively [64]. Davis
and co-workers also performed size exclusion chroma-
tography of OVCA433 cell culture supernatant on a Seph-
arose CL-4B column, a matrix with a size exclusion limit
of 6 × 104 – 2 × 107 Da for globular proteins. These chro-
matography studies demonstrated that CA125 activity
was contained in fractions having molecular masses of
200,000-1 million Da [64].
Importantly, the report by Davis et al. conclusively re-
futed a previous claim that CA125 was a carbohydrate epi-
tope [63,64]. Oxidation of the CA125-containing fractions
at pH 4.5 with 1 mM and 10 mM sodium periodate—con-
ditions that oxidize vicinal hydroxyls of terminal sialic acid
or those present in the entire oligosaccharide chains, re-
spectively [65,66]—did not result in significant loss of
OC125 binding to the antigen. Instead, exposure to heat
and low pH (100°C, 3.3 pH), protease digestion, reduction
and alkylation in buffer containing 4 M guanidine hydro-
chloride abrogated binding of OC125 to the antigen. These
crucial observations suggested that CA125 was a confor-
mationally dependent peptide epitope present in a high
molecular weight mucin. Although some incremental ad-
vances in our understanding of the molecule were gainedfrom important fundamental research conducted inde-
pendently by Lloyd and O’Brien [20,56,57,62,67-70],
major advance in our understanding of the biochemistry
of CA125 was gained from the identification of MUC16
as the mucin that contained this antigen.
MUC16, a large molecular weight membrane-spanning
mucin
Molecular cloning of MUC16 revealed it to be a mucinous
glycoprotein with an average molecular weight between
3–5 million Da [21,22,71,72]. Similar to other membrane-
spanning mucins, MUC16 (Figure 1) is composed of a tan-
dem repeat region sandwiched between N-terminal and
C-terminal domains [21,22]. The C-terminal domain is
the smallest part of the molecule and is composed of 284
amino acids (Figure 1). While it has been proposed that
this C-terminal domain can be phosphorylated under spe-
cific conditions, conclusive proof is lacking [21,73,74].
The N-terminal region is composed of 12,068 amino
acids [71]. Other than potential sites for both N-linked
and O-linked glycosylation, there are no major structural
features identified in this domain. The tandem repeat
domain is composed of up to 60 repeats (Figure 1). Each
repeat has 156 amino acids [21]. The primary amino
acid sequence in each repeat is not identical but is hom-
ologous. Two conserved cysteines, at positions 59 and
79 of each repeat, are proposed to have structural sig-
nificance [21]. These cysteines could form intra- as well
as inter-molecular disulfide bonds. While the intramo-
lecular disulfide bonds could form loops within each
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contribute to formation of an extracellular matrix [71].
Evidence supporting the location of CA125 antigen in
the MUC16 tandem repeat came from two initial studies
where the tandem repeats were expressed in E. coli or in
human ovarian cancer cell lines [21,72]. In the first study,
the 11th MUC16 tandem repeat (R11) was expressed and
isolated from E. coli [21]. This recombinant R11 protein
was recognized by the three anti-CA125 antibodies M11,
OC125 and OV197. In another study, a recombinant pro-
tein containing three of the MUC16 tandem repeats was
produced in two cell lines—SW626 and SKOV-3—that do
not express MUC16 [72]. The recombinant proteins
expressed in these cell lines were detected by M11 and
OC125 but not by the VK8 antibody. This finding was in-
teresting because VK8 was initially classified as an M11-
type antibody, but studies with the recombinant MUC16
fragments demonstrated clear differences in the epitope
specificities of M11 and VK8 [72].
Digestion of the recombinant R11 tandem repeat by the
endoproteases Lys-C or Asp-D completely destroyed the
CA125 epitope as demonstrated by the observation that
the resulting fragments were not detected by the OC125
or M11 antibodies [21]. It was primarily this one experi-
ment that led to the prevalent viewpoint that the CA125
epitope is located in the 21-amino acid loop of the tandem
repeats formed by disulfide bridging of cysteines located at
positions 59 and 79. Recent experiments conducted by us
and by Bressan et al. [75] have led us to believe that this
model is inaccurate and that the CA125 epitope has not
been sufficiently characterized.
In our experiments we did not observe binding of
OC125 and M11 antibodies to a synthetic 21-mer peptide
sequence (Peptide 1) comprising the loop region shared
by eight of the 60 MUC16 tandem repeats. We also inves-
tigated OC125 and M11 binding to three variants of Pep-
tide 1 that differ in single amino acids (C21A, Peptide 3;
P8S, Peptide 4) or in two amino acids (P8S and C21A,
Peptide 5). These variants were selected because their se-
quences are also found in the MUC16 repeats (Ser appears
in position 8 in ~25% of tandem repeats) or they produce
specific modifications in the secondary structures of the
peptides (replacing Cys with Ala removes the possibility of
intramolecular disulfide bonding) [76]. In five independent
assay protocols—Silicon Photonic Microring Resonator
Immunoassay, Surface Plasmon Resonance Immunoassay,
ELISA, Competitive ELISA and Affinity Probe Capillary
Electrophoresis—none of these four peptides were recog-
nized by OC125 and M11 antibodies.
Not all of the MUC16 repeats are recognized to the
same extent by these antibodies [75]. Recombinant pro-
teins containing either R2, R7, R9, R11, R25, or R51 re-
peats were recognized by M11 in Western blot assays.
However, only a subset of these repeats (R9, R11, R25,and R51) were detected strongly by OC125 and a partially
overlapping subset (R2, R9, R25, and R51) were detected
by OV197 antibodies. Deletion mutants of the 156 amino
acid R25 repeat that are missing residues 129–156 from
the C-terminal end retain binding by OC125, M11 and
OV-197. However, deletion of the amino acids 1–30 from
the N-terminal end of this truncated mutant abrogated
binding by all three antibodies. Thus the CA125 epitope is
likely localized between amino acids 1–128 of the MUC16
repeats [75]. However, any further refined characterization
of the CA125 epitope has not been achieved.
Incidentally, the region 1–128 of R25 contains the Sea
urchin Enterokinase and Agrin (SEA) domain [71,77,78].
In fact BLAST protein homology search shows the pres-
ence of SEA domains in each of the MUC16 tandem re-
peats (Additional file 1). In addition, one SEA domain is
also located in the C-terminal region of the mucin. While
MUC1 and some other mucins are known to contain a
single or limited number of SEA domains, such extensive
presentation of these structural units is unique to MUC16
among all of the identified mammalian mucins. One SEA
domain from the murine Muc16 ortholog has been struc-
turally characterized [78]. While SEA domains can exhibit
autoproteolytic activity, any potential importance of this
domain in the shedding of MUC16 is not clear.
Antibodies that recognize continuous epitopes are likely
to bind sequences that are composed of not more than
15–22 amino acids of which 5–6 residues are critical as
they provide maximum binding energy [79]. However, de-
letion of even 30 amino acids from the N- or the C-
terminal end of the 128 amino acid recombinant repeat
domain abrogates antibody binding [75]. These results
have prompted the suggestion that the CA125 epitope is
not continuous but is instead a discontinuous epitope that
is dependent on the secondary conformational structure
of the MUC16 tandem repeat [75]. While this suggestion
is consistent with our studies with the C-loop peptides, its
acceptance relies on the proposal that detection of the 1–
128 deletion mutant by the CA125 antibodies in western
blots follows renaturation during transfer to the nitrocel-
lulose membrane [75]. One important conclusion drawn
from our studies with the peptides and those reported by
Bressan et al. is that the CA125 epitope most likely does
not reside in the loop region of the tandem repeat as pre-
dicted initially [21,75]. The implications of this conclusion
are serious as it indicates that even though the CA125
assay is routinely used to monitor the vast majority of pa-
tients with serous ovarian cancer, the exact molecular na-
ture of the antigen is not accurately characterized.
The CA125 II assay currently used to measure serum
concentrations of this biomarker in patients uses M11 as
a capture antibody and OC125 as a tracer [13,56,70].
Studies with recombinant R11 indicate that binding of
OC125 to this antigen is enhanced several-fold after pre-
Figure 2 OC125 weakly binds to cells that are generally
considered negative for MUC16. SKOV-3 cells (identity confirmed
by STR analysis) were stained with the primary (1°) antibodies OC125
or VK8 followed by incubation with allophycocyanine (APC)-labeled
donkey anti-mouse (DAM) secondary antibody. Binding of the
antibodies to SKOV-3 cells was determined on a LSR-II flow
cytometer. RT-PCR using MUC16 primers previously reported [178],
was used to determine expression of MUC16 in OVCAR-3, ECC-1 and
SKOV-3 cells (data not shown).
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ition—of OC125 binding is also observed with other re-
combinant repeats of MUC16, or the entire molecule in
patient sera, needs to be determined. A corollary to this
statement is that since OC125 binding is sensitive to the
molecular environment of its epitope, other factors such
as post-translational modification may influence detec-
tion of CA125 in patient sera.
In our experiments with ovarian cancer cell lines, we
have observed that OC125 weakly binds to the surface
of cells—SKOV-3 and A2780—that are generally con-
sidered to be non-expressors of MUC16. However,
under the same conditions another anti-CA125 anti-
body, VK8, which was used in the initial cloning experi-
ments [22,57], does not recognize SKOV-3 (Figure 2).
The marginal binding of OC125 to SKOV-3 cells corre-
sponds to weak expression of MUC16 as determined by
RT-PCR (data not shown).
We observe that trypsin digestion significantly re-
duces VK8 binding to MUC16-expressing cells, but only
slightly reduces OC125 binding to cells under the same
conditions (Figure 3). We tested the possibility that
even after trypsin digestion the OC125 epitopes remain
bound to the cell surface via disulfide bridges. Mild
treatment of the cells with mercaptoethanol or dithio-
threitol to release disulfide-bound moieties did not de-
crease OC125 binding to the trypsinized OVCAR-3
cells (Figure 3).
If CA125 is indeed a discontinuous epitope, it is not
clear if the O- or N-glycosylation of the tandem repeat will
influence binding of OC125, M11 or OV197. Most studies
characterizing the MUC16 repeats have been conducted
with recombinant proteins produced in bacterial cells
[21,75] and therefore lacking native glycosylation. Similarly
our 21mer peptides, assembled by solid-phase peptide syn-
thesis, are not glycosylated. After initial characterization of
the glycosylation of MUC16 [80], there has not been a ro-
bust and systematic characterization of the glycan chains
attached to each domain of the mucin or of the glycan
site occupancy in mucin molecules produced by tumor
versus normal epithelial cells. Attempts to identify disease-
specific MUC16 glycoforms by glycomic analysis are pro-
ducing interesting results that may enhance the diagnostic
potential of this mucin [81-88]. However, with the enor-
mous potential diversity in glycan chains and glycoforms a
significant effort will be required to fully understand the
post-translational status of this mucin and its effect on de-
tection in the CA125 assay and systemic half-life of the
MUC16 glycoforms.
Mucins in systemic circulation are rapidly processed
by the reticulo-endothelial cells, leaving behind only a
fraction of the mucins in circulation to be detected in
clinical assays such as the CA125 test [89]. The com-
bined effects of MUC16 clearance—reducing the amountof circulating MUC16 to miniscule levels—and the inabil-
ity of the antibodies to uniformly bind all tandem repeats
and isoforms—undercounting circulating MUC16—sug-
gests that the CA125 assay significantly underestimates
the concentration of this biomarker. New generation of re-
agents and assay protocols that can capture and more ac-
curately quantify a larger cohort of the MUC16 molecules
will likely add to the clinical significance of this biomarker.
To date, the majority of the anti-MUC16 antibodies
raised against full-length mucin recognize regions within
the tandem repeat domains [58,59]. An explanation for
the bias toward antibodies that recognize the tandem re-
peat region of MUC16 is not available but is likely due
to higher immunogenicity of these epitopes. Antibodies
against defined epitopes that are outside of the tandem
repeat region (against peptides from the carboxy ter-
minal end [90,91], for example) will serve an important
purpose in modifying the CA125 assays and also in at-
tempts to understand the biology of this mucin.Biological role of MUC16
MUC16 is expressed by normal bronchial, endometrial,
ovarian and corneal epithelial cells and has evolved
from the proteoglycan, agrin [24,92-98]. A transmem-
brane region anchors the mucin in the cell membrane
Figure 3 Cell surface MUC16 is sensitive to proteolysis. A, Binding of OC125 and VK8 to OVCAR-3 cells that were harvested with trypsin or
EDTA containing media was determined by flow cytometry. A significant decrease in VK8 binding to cells harvested after trypsin treatment was
observed whereas under these conditions, OC125 binding was less affected. B, Reduction of the trypsinized OVCAR-3 cells with dithiothreitol
(DTT) or 2-mercaptoethanol (2-ME) did not result in additional loss of OC125 binding to the cells. In all experiments, a fluorescently tagged goat
anti-mouse antibody was used for detection.
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surface (Figure 4).
MUC16 is released from the cell surface following pro-
teolytic cleavage at a site presumably 50 amino acids up-
stream of its transmembrane segment [21]. As a resultFigure 4 MUC16 on the surface of ovarian cancer cells. OVCAR-3 cells w
with goat anti-mouse secondary antibody. A, low magnification secondary ele
Microscopy (SEM) image of OVCAR-3 showing colloidal gold nanoparticles bin
same cell surface shown in B, clearly showing the colloidal gold nanoparticles
colloidal gold nanoparticles. OVCAR-3 cells are not labeled with colloidal goldthe proteolytically released ectodomain of MUC16 is not
significantly different in molecular weight than the cell
surface-bound intact mucin.
Neutrophil elastase, MMP-7, MMP-9 and bacterial
metalloprotease (ZmpC) can release the ectodomain ofere labeled with VK8 followed by colloidal gold nanoparticles conjugated
ctron image of two labeled OVCAR-3 cells. B, Scanning Electron
ding to cell surface and microvilli. C, Back scattered electron image of
. Bright spots (some indicated by bright arrows) in B and C are the
nanoparticles in the absence of VK-8 (data not shown).
Figure 5 Model for MUC16-induced NK cell inhibition. MUC16
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pecially glycosylation) around the site of cleavage are
thought to regulate the release of the ectodomains of
these mucins [100]. Post-translational modifications
around the cleavage site may be a variable that impacts
the sensitivity of the CA125 assay.
In corneal epithelial cells, MUC16-Galectin-3 inter-
action has been shown to serve as a barrier for bacterial
and viral infections in ocular epithelia [102,103]. These
are the first studies to show a potential biological role
for MUC16 in non-cancer cells. However, knockdown of
murine Muc16 does not result in any obvious functional
deficit [104,105]. Since these knockout mice were main-
tained in a pathogen free environment and were not
otherwise challenged with chemical or biological agents,
the potential impact of Muc16 knockdown in specific
pathological states remains unknown. Further explor-
ation into the normal physiologic role(s) of human and
murine MUC16 is warranted.released from tumors binds to naïve NK cells (shown in red) and along
with other tumor derived factors induces a phenotypic and functional
change. The altered NK cells (shown in blue) secrete cytokines that
promote angiogenesis. The cell surface bound MUC16, on the other hand,
acts as an anti-adhesive mucin and blocks the interaction between the NK
cells and ovarian tumor cells thereby preventing cancer cell cytolysis.Immunoprotection of cancer cell cells
Innate immune cells, Natural Killer (NK) cells and mono-
cytes are unable to attack tumor cells expressing high
levels of MUC16 [106]. Knockdown of MUC16 results in
increased lysis of the ovarian cancer cells by the cytolytic
NK cells. The mechanism by which MUC16 inhibits NK
cell-mediated killing of cancer cells is under investigation.
One proposal is that MUC16 acts as a barrier that pre-
vents interaction between the NK cells and their targets
[106]. NK cells require physical contact with the target
cells for cytolysis to occur. NK cell immunologic synapse
is defined by polarization of cytoskeletal and cell signaling
molecules along with cytolytic granules of the effector
cells to the site of contact [107-109]. The NK cell cytolytic
granules are released into the target cells, triggering cell
death via apoptosis. MUC16 with its ~5 million Da mo-
lecular size is expected to have a linear length of 1–5 μm
[106,110]. Due to its extended structure and overall nega-
tive charge (due to the presence of terminal sialic acid res-
idues [80]), MUC16 may inhibit intimate interactions
between NK and cancer cells. This situation is analogous
to the mechanism of immuneprotection demonstrated for
MUC4 [111].
Imunoprotective effect by MUC16 may also arise from
its interaction with the NK cell inhibitory receptor, Siglec-9
(Figure 5) [112]. NK cells express both activating (NKG2D,
CD16, DNAM-1, for example) and inhibitory receptors
(Killer Immunoglobulin-like Receptors (KIR’s), Siglec-9,
and Siglec-7, for example) on their cell surface. Interaction
of activating and inhibiting receptors with their correspond-
ing ligands on target cells leads to either activation or inhib-
ition of the NK cell cytolytic response (reviewed in [113]
and other articles). The interplay between the activatingand inhibitory receptors controls the cytolytic activity of
NK cells.
Siglecs are a class of inhibitory receptors that bind to
negatively charged sialic acid ligands [114-119]. MUC16
oligosaccharides carry sialic acid in a terminal α2-3 linkage
[80]. Oligosaccharides terminated with α2-3-linked sialic
acids are recognized as ligands by the inhibitory Siglec-9
receptor [120]. Our work demonstrates that MUC16-
Siglec-9 interaction protects cancer cells from NK cell at-
tack. Siglec-9 is also expressed on monocytes and MUC16
promotes binding of monocytes to cancer cells. Upon
binding to its ligand, Siglec-9 is phosphorylated on its
Immunoreceptor Tyrosine-based Inhibition Motif (ITIM)
tail, triggering an inhibitory signaling cascade that results
in inhibition of the NK cell response [121]. Ovarian cancer
cells are therefore likely to be protected from NK cell and
monocyte attack due to the negative signaling induced via
MUC16-Siglec-9 interaction (Figure 5). This type of pro-
tection can occur from interaction of the NK and mono-
cyte Siglec-9 with MUC16 on the surface of cancer cells
and also from circulating MUC16 molecules cleaved from
the cancer cells via proteolysis.
MUC16 protects ovarian cancer cells from naïve un-
stimulated NK cells as well as IL-2 stimulated NK cells. A
recent study has implicated MUC16 in inhibiting target cell
killing via Antibody-dependent Cell-Mediated Cytotoxicity
(ADCC) [122], suggesting that the mucin may dampen
the response of immunotherapeutic antibodies.
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express low levels of MUC16 on their cell surface [106].
As a result, tumor cells surviving NK cell attack are high
expressors of MUC16 that are more resistant to immune
attack. We have proposed that NK cells contribute to
immune editing [123-125] by selectively lysing cancer
cells expressing lower levels of MUC16. As a result,
those cancer cells with high levels of MUC16, the subset
that is most likely to resist immune attack, survive.
Pro-metastasis role of MUC16
Immune editing in favor of cancer cells expressing higher
levels of MUC16 may also increase peritoneal metastasis of
ovarian tumors [126-129]. MUC16 binds to mesothelin, a
GPI-anchored glycoprotein found on the surface of meso-
thelial cells and also overexpressed by ovarian tumors, with
an apparent Kd of 5 nM [23,130,131]. MUC16-mesothelin
interaction allows tumor cells to bind to themselves (likely
increasing tumor mass at metastatic sites) and also allows
attachment of ovarian cancer cells to the mesothelial lining
[130]. Removal of N-glycans from MUC16 attenuates its
interaction with mesothelin [132]. Mesothelin, similar to
other members of its superfamily, contains superhelical
ARM-type repeats that could potentially recognize carbo-
hydrate ligands presented by MUC16 [132].
MUC16, via its sialofucosylated oligosaccharides, binds
to both E- and L-selectin even under shear stress condi-
tions [133]. Contribution of MUC16-selectin interaction
to ovarian cancer progression or metastasis is not known.
Even after MUC16 knockdown, E- and L-selectin binding
is observed to cancer cells, presumably via other glyco-
lipid, mucin, or glycoprotein ligands [133]. Therefore, in-
terpretation of results MUC16-selectin interactions and
their possible roles in metastasis are complicated by pres-
ence of such redundant binding mechanisms.
MUC16 associated cell signaling
MUC1 and MUC4 undergo auto-cleavage during their
synthesis to generate α- and β-subunits [134-136]. The β-
subunit of MUC1 and MUC4 is involved in intracellular
signaling. For example, EGF stimulation causes the MUC1
β-subunit to signal via PI3K and MAPK [137,138] MUC1
β-subunit also interacts with p53, NF-κB, β-catenin and
STAT1 [139,140].
Phosphorylation of the cytoplasmic portion of C-
terminal domain of MUC16 increases shedding of the
ectodomain of this mucin [74]. Specific serine, threo-
nine and tyrosine residues in the cytoplasmic tail of
MUC16 have been proposed as likely candidates for
phosphorylation [21].
Knockdown of MUC16 inhibits in vitro and in vivo
proliferation of cancer cells [141-143] MUC16-triggered
activation of STAT3 via JAK2 results in increasing can-
cer cell proliferation. On the other hand, knockdown ofMUC16 causes cell cycle arrest (either in G2/M or G1
phase) and apoptosis [143,144].
Expression of the C-terminal domain of the mucin in
the MUC16neg SKOV-3 cells increases their proliferation
with 2–3 fold increase in tumor weight and a significant
decrease in survival of tumor-bearing mice [142].
MUC16 knockdown causes a decrease in the expression
of matrix metalloproteases (MMP-2), a class of proteo-
lytic enzymes that plays a crucial role in cancer cell me-
tastasis [144-146]. A recent report suggests that the
cytoplasmic tail of MUC16 interacts with Src-family ki-
nases and induces E-cadherin-mediated cell invasion
and migration [147].
MUC16 is overexpressed but not associated with
decreased survival or chemoresistance
Silencing of MUC16 increased the sensitivity of OVCAR-3
cells to cisplatin and doxorubicin but not to paclitaxel
[141]. However, bioinformatics analysis of MUC16 ex-
pression and mutations available through The Cancer
Genome Atlas (TCGA) [148] does not support a major
effect of MUC16 on overall survival in ovarian cancer
patients (Figure 6). No correlation is observed between
MUC16 expression and resistance to chemotherapy in
the ovarian cancer cohorts. Of the patients on whom
MUC16 data has been deposited in TCGA, mutations
in the mucin were identified in fifteen of 196 patients
(Additional file 2). Patients with mutated MUC16 had a
slightly lower survival than patients with wild-type
MUC16; however the difference was not statistically sig-
nificant (Figure 6).
MUC16 as a target for therapy
The lack of significant effect of MUC16 observed in our
analysis of TCGA data is inconsistent with the effect of
MUC16 observed in in vitro and in vivo studies with
ovarian and breast cancer cells, described above, where
the expression of this mucin was attenuated. This di-
chotomy may potentially arise from the fact that only
eight healthy donor samples are reported in the TCGA
database for ovarian cancer. We estimate that data from
40 individuals each in the healthy control and ovarian
cancer group will be required to attain 90% power to
demonstrate the effect of differential MUC16 gene ex-
pression on patient survival. If no correlation between
MUC16 expression and survival is demonstrated in a
larger study, an intriguing possibility that will have to be
considered is that MUC16 may be a factor whose pres-
ence (in terms of biological significance) is felt only by
its absence (as shown by the knockdown experiments).
If true, this model suggests that significant effect on
ovarian tumors may be achieved by the application of
small molecule agents and other strategies for in vivo
knockdown of MUC16 or inhibition of its biological
Figure 6 Analysis of data on MUC16 available through TCGA analysis of ovarian cancer samples. A TCGA data set [148] was analyzed to
determine differential expression of prominent cancer-related genes between normal ovarian tissue and ovarian carcinoma (heat map in top
panel). Although MUC16 is upregulated in the cancer samples (expression in cancer specimens is double than in normal) this difference is not
significant (p-value = 0.1), probably because there were only 8 normal samples in TCGA dataset. MUC16 is compared to other prominent mutated
genes reported in the original TCGA report [148]. Of these genes, only BRCA2 is differentially expressed between normal and cancer (p-value <0.001)
samples. Analysis of mutated and wild-type MUC16 expression in samples from ovarian cancer patients listed in TCGA is shown in the heat map in
the lower panel. Mutated MUC16 is also mildly over-expressed as compared to wild-type mucin (expression Wild-type/Mutated = 0.94), however this
difference is not significant (p-value = 0.84). MUC16 is compared to other genes reported to be highly mutated at the original report of TCGA. None
of the other genes is differentially expressed between MUC16-wild-type and MUC16-mutated ovarian cancer specimens, indicating no association
between MUC16 mutation status and key genes expression in this dataset (p-value <0.05). B, Survival of ovarian cancer patients with wild-type and
mutated MUC16 was compared. Although a trend was observed suggesting worse outcome in patients with mutated MUC16, the difference was
not statistically significant (p-value = 0.28). C, MUC16 (both mutated and wild-type) expression was divided into quartiles. Survival of patients in each
of these quartiles was not significantly different.
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increased apoptosis, decreased proliferation, increased
sensitivity to chemotherapy, and reduced efficiency in
subverting innate immune responses and immunothera-
peutic agents. In this context it is interesting to note that
microRNA-200c regulates expression of both MUC4 and
MUC16 [149].
MUC16 as a target for immunotherapy
Anti-mesothelin antibodies that interfere with mesothelin-
MUC16 binding have been developed as immunothera-
peutic agents [150-153]. A novel immunoadhesin, HN125,
contains the MUC16 binding epitope of mesothelin fused
to the Fc portion of human IgG1 antibody has been devel-
oped [154,155]. However, additional work is required to
increase the potency of HN125 to produce a stronger
anti-cancer response.
Oregovomab and Abgovomab are two antibodies de-
veloped for ovarian cancer immunotherapy. Oregovomab,
(B43.13, OVAREX) is a mouse anti-MUC16 antibody de-
veloped for the in vivo detection of ovarian tumors [156].
A retrospective analysis of results trials designed to test
the use of B43.13 as an imaging agent suggested increased
survival in patients developing a human anti-mouse anti-
body (HAMA) response [157]. Repeated administration of
the anti-CA125 antibodies results in increased anti-tumor
T cell responses and the generation of anti-idiotypic anti-
bodies [158-165]. These positive results led to the testing
of Oregovomab in larger clinical trials in ovarian cancer
patients [166,167]. Overall the results of these trials were
disappointing as no benefit of Oregovomab was observed.
Abgovomab has met a similar fate in clinical trials.
Abgovomab is an anti-idiotype antibody that was devel-
oped as a targeting agent against MUC16 [168-172]. Here
again, clinical trials showed no difference in the overall
survival of ovarian cancer patients as compared to patients
in the control arm of the study [173-176].
One potential reason for Oregovomab and Abgovomab
being unsuccessful in inhibiting tumor growth is that these
antibodies may conjugate with the circulating ectodomain
of MUC16 reducing the amount of antibody available to
target the cancer cells. Additionally, shedding of the ecto-
domain may release the antibodies bound to the cell sur-
face associated mucin. The rate at which the ectodomain is
shed and the factors controlling the proteolysis of MUC16
are not clearly defined. It will be interesting to determine
the efficacy of treatment regimens that combine anti-
MUC16 antibodies with agents that can inhibit MUC16 re-
lease in controlling the growth of ovarian tumors.
Targeting MUC16 with antibody-drug conjugates
Two anti-MUC16 antibodies, 3A5 and 11D10, were devel-
oped and conjugated to the cytotoxic drug Monomethyl
auristatin E (MMAE). 3A5 targets MUC16 tandem repeatsand is more effective than 11D10 in delivering MMAE to
cancer cells and inducing cell death. The 3A5-MMAE
conjugate (now referred to as DMUC5754A) is being
tested in a Phase I clinical trial. Twenty two of the 44 pa-
tients recruited in this trial received DMUC5754A [177].
The antibody drug conjugate produced minimal toxicity
and, importantly, one patient showed complete response
and five patients experienced a reduction in tumor. These
results are encouraging and support further development
of MUC16-targeted therapies for cancer.
Conclusion
Recent studies on MUC16 indicate that this mucin is not
only important because it contains the biomarker CA125
but also for its role in contributing to ovarian tumor growth
and metastasis. The complex biochemical structure of this
mucin continues to provide major challenges to efforts be-
ing undertaken to make improvements to the CA125 assay
and to understand the biological role of MUC16. The com-
plexity of this antigen however also provides multiple op-
portunities that can be exploited to develop a test that can
monitor this mucin even at low concentrations and, as the
encouraging results with DMUC5754A suggest, developing
novel anti-cancer therapeutic strategies. A sustained and
systematic effort will be required to fully understand and
exploit MUC16 to realize a benefit for patients with ovarian
and other malignancies.
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